Zoldonrasib

DRUG2 trials

Sponsors

Revolution Medicines, Inc.

Conditions

Advanced Solid TumorsCRCColorectal Cancer (CRC)Metastatic Solid TumorsNSCLCNon-small Cell Lung Cancer (NSCLC)PDACPDAC - Pancreatic Ductal Adenocarcinoma

Phase 1

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

RecruitingNCT07397338

Revolution Medicines, Inc.Advanced Solid Tumors, Colorectal Cancer (CRC), CRC +3

Start: 2026-01-30End: 2029-05-01Target: 370Updated: 2026-07-16

Phase 3

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

RecruitingNCT07621718

Revolution Medicines, Inc.Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenosquamous Carcinoma +5

Start: 2026-05-22End: 2030-04-22Target: 670Updated: 2026-07-08